Riegelnegg, M. and Jeindl, R. (2023): Autologous fat grafting in osteoarthritis. Rapid Review Nr.: 007.

Jeindl, R. and Mayer-Ferbas, J. and Erdös, J. (2023): Endovenous laser therapy for varicose veins in the lower extremities. Rapid Review Nr.: 008.

Huic, M. and Goetz, G. (2023): Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques. HTA-Projektbericht 156.

Jeindl, R. and Riegelnegg, M. (2023): Robot-assisted rehabilitation for incomplete spinal cord injury. Rapid Review Nr.: 005.

Giess, D. and Erdos, J. and Wild, C. (2023): SMA-Therapies: Mid- to longer-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec as monotherapies or in combination, and patients treated for ≥12 months with risdiplam as monotherapy or in combination. AIHTA Policy Brief 001/ 2. Update.

Wolf, S. and Reinsperger, I. (2023): Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity. HTA-Projektbericht 155.

Ettinger, S. and Wild, C. (2023): CORE-MD Roadmap for Education & Training: Perceived training needs of regulators, notified bodies and clinicians for successful implementation of the EU MDR. AIHTA Policy Brief 000.

Mayer-Ferbas, J. and Riegelnegg, M. and Jeindl, R. (2023): Myopia control spectacle lenses for children and adolescents. Rapid Review Nr.: 006.

Strohmaier, C. and Kern, J. (2023): Registries in Austria and their utilisation for healthcare improvement. HTA-Projektbericht 157.

Rothschedl, E. and Grössmann, N. (2023): Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM). Fact Sheet Nr. 157.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC). Fact Sheet Nr. 158.

Rothschedl, E. and Grössmann, N. (2023): Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 159.

Rothschedl, E. and Grössmann, N. (2023): Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Fact Sheet Nr. 160.

Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update September 2024. Fact Sheet Nr. 161.

Ettinger, S. and Jeindl, R. and Erdös, J. (2023): Biomarkers in Alzheimer's Disease. Rapid Review Nr.: 004.

Rothschedl, E. and Grössmann, N. (2023): Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL). Fact Sheet Nr. 151.

Rothschedl, E. and Grössmann, N. (2023): Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 152.

Rothschedl, E. and Grössmann, N. (2023): Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC). Fact Sheet Nr. 153.

Rothschedl, E. and Grössmann, N. (2023): Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC). Fact Sheet Nr. 154.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Rothschedl, E. and Grössmann, N. (2023): Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Fact Sheet Nr. 156.

Buzath, K. and Zechmeister-Koss, I. (2023): Economic Dimensions of Community Nursing: A Systematic Literature Review. HTA-Projektbericht 153.

Rothschedl, E. and Grössmann, N. (2023): Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma. Update February 2024. Fact Sheet Nr. 146.

Rothschedl, E. and Grössmann, N. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation. Update April 2024. Fact Sheet Nr. 147.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC). Update April 2024. Fact Sheet Nr. 148.

Rothschedl, E. and Grössmann, N. (2023): Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM). Fact Sheet Nr. 149.

Rothschedl, E. and Grössmann, N. (2023): Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML). Update February 2024. Fact Sheet Nr. 150.

Riegelnegg, M. and Gassner, L. and Grössmann-Waniek, N. (2023): Robot-assisted surgery in thoracic and visceral indications – Update 2023. HTA-Projektbericht 108/ Update 2023.

Rothschedl, E. and Grössmann, N. (2023): Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Update June 2024. Fact Sheet Nr. 138.

Rothschedl, E. and Grössmann, N. (2023): Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update December 2023. Fact Sheet Nr. 139.

Rothschedl, E. and Grössmann, N. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023. Fact Sheet Nr. 140.

Rothschedl, E. and Grössmann, N. (2023): Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Update December 2023. Fact Sheet Nr. 141.

Rothschedl, E. and Grössmann, N. (2023): Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC). Update February 2024. Fact Sheet Nr. 143.

Rothschedl, E. and Grössmann, N. (2023): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023. Fact Sheet Nr. 144.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

Rothschedl, E. and Grössmann, N. (2023): Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 135.

Rothschedl, E. and Grössmann, N. (2023): Trifluridine/tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC). Update October 2023. Fact Sheet Nr. 136.

Rothschedl, E. and Grössmann, N. (2023): Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Update October 2023. Fact Sheet Nr. 137.

Rothschedl, E. and Grössmann, N. (2023): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Update July 2024. Fact Sheet Nr. 142.

Jeindl, R. and Ettinger, S. (2023): Radiofrequency denervation for chronic lumbar or cervical spine pain. Rapid Review Nr.: 003.

Rothschedl, E. and Wolf, S. (2023): Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 133.

Rothschedl, E. and Wolf, S. (2023): Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer. Update October 2023. Fact Sheet Nr. 134.

Gregor-Patera, N. (2023): Sponsoring of patient initiatives in Austria. 5th Update of the Systematic Analyses 2014 to 2019. AIHTA Policy Brief 007/ 5. Update.

Rothschedl, E. and Grössmann, N. (2023): Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 130.

Rothschedl, E. and Grössmann, N. (2023): Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). Update December 2023. Fact Sheet Nr. 131.

Rothschedl, E. and Wolf, S. (2023): Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma. Update July 2023. Fact Sheet Nr. 132.

Rothschedl, E. and Wolf, S. (2023): Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update July 2023. Fact Sheet Nr. 125.

Rothschedl, E. and Wolf, S. (2023): Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update June 2023. Fact Sheet Nr. 126.

Rothschedl, E. and Grössmann, N. (2023): Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma. Update February 2024. Fact Sheet Nr. 127.

Rothschedl, E. and Wolf, S. (2023): Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023. Fact Sheet Nr. 128.

Auinger, D. and Sehic, O. (2023): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003/ 3. Update.

Rothschedl, E. and Wolf, S. (2023): Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update July 2023. Fact Sheet Nr. 129.

Jeindl, R. and Ettinger, S. (2023): iv Immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss. Rapid Review Nr.: 001.

Jeindl, R. and Ettinger, S. (2023): Extracorporeal shock wave therapy for orthopaedic indications. Rapid Review Nr.: 002.

Huic, M. and Reinsperger, I. (2023): Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements. HTA-Projektbericht 152.

Zechmeister-Koss, I. (2023): Perinatal and infant mental health care in Austria: A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol. HTA-Projektbericht 151.

Semlitsch, T. and Loder, C. (2023): Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. 2nd Update 2023. Decision Support Document 41/ Update 2023.

Hofer, V. and Goetz, G. (2023): Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas. 1st Update 2023. Decision Support Document 111/ Update 2023.

Wolf, S. and Al Froukh, R.F. (2023): 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023. Decision Support Document 118/ Update 2023.

Forel, D. and Vandepeer, M. and Ma, N. and Goetz, G. (2023): Percutaneous aspiration thrombectomy for pulmonary embolism. Decision Support Document 135.

Gassner, L. and Al Froukh, R.F. and Goetz, G. (2023): Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor. Decision Support Document 136.

Johansson, T. and Freundlinger, N. and Strohmaier, C. (2023): Bleomycin Electrosclerotherapy for Vascular Anomalies: Systematic Review. Decision Support Document 137.

Scott, A. and Hofer, V. and Al Froukh, R.F. and Ma, N. (2023): Electrical auricular vagus nerve stimulation for pain. Decision Support Document 138.

Rothschedl, E. and Wolf, S. (2023): Nadofaragene firadenovec (Adstiladrin®) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. Update June 2023. Fact Sheet Nr. 121.

Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 117.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023. Oncology Fact Sheet Nr. 118.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update April 2023. Oncology Fact Sheet Nr. 119.

Rothschedl, E. and Wolf, S. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer. Update April 2023. Oncology Fact Sheet Nr. 120.

Rothschedl, E. and Wolf, S. (2023): Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023. Fact Sheet Nr. 122.

Rothschedl, E. and Wolf, S. (2023): Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone‑sensitive prostate cancer (mHSPC). Update June 2023. Fact Sheet Nr. 123.

Ettinger, S. and Jeindl, R. (2023): Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid α‑glucosidase [GAA] deficiency). Fact Sheet Nr. 124.

AIHTA, HTA Austria (2023): Annual Report 2022.